{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:23:05Z","timestamp":1791415385040,"version":"4.3.3"},"reference-count":153,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.mayocp.2017.02.011","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T03:45:11Z","timestamp":1496375111000},"page":"978-994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Alzheimer Disease"],"prefix":"10.1016","volume":"92","author":[{"given":"Richard J.","family":"Caselli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Knopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neill R.","family":"Graff-Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2017.02.011_bib1","first-page":"146","article-title":"\u00dcber eine eigenartige Erkrankung der Hirnrinde","volume":"64","author":"Alzheimer","year":"1907","journal-title":"Allemagne Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1976.00500040001001","article-title":"Editorial: The prevalence and malignancy of Alzheimer disease. A major killer","volume":"33","author":"Katzman","year":"1976","journal-title":"Arch Neurol"},{"issue":"3 suppl","key":"10.1016\/j.mayocp.2017.02.011_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3233\/JAD-2006-9S313","article-title":"My own experience in early research on Alzheimer disease","volume":"9","author":"Terry","year":"2006","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"16","key":"10.1016\/j.mayocp.2017.02.011_bib4","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1001\/jama.1995.03520400044042","article-title":"Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals","volume":"273","author":"Petersen","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.02.011_bib6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1212\/WNL.56.9.1133","article-title":"Practice parameter: early detection of dementia: mild cognitive impairment (an\u00a0evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Petersen","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.mayocp.2017.02.011_bib7","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/archneur.58.12.1985","article-title":"Current concepts in mild cognitive impairment","volume":"58","author":"Petersen","year":"2001","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment\u2014beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment","volume":"256","author":"Winblad","year":"2004","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1212\/01.WNL.0000132523.27540.81","article-title":"Mild cognitive impairment, amnestic type: an epidemiologic study","volume":"63","author":"Ganguli","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archneur.58.3.397","article-title":"Mild cognitive impairment represents early-stage Alzheimer disease","volume":"58","author":"Morris","year":"2001","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/archneur.63.5.674","article-title":"Neuropathologic outcome of mild cognitive impairment following progression to dementia","volume":"63","author":"Jicha","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mayocp.2017.02.011_bib12","series-title":"The Uniform Data Set, Version 3.0","year":"2015"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workshops on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.mayocp.2017.02.011_bib14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/01.WNL.0000140289.18472.15","article-title":"Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy","volume":"63","author":"Tang-Wai","year":"2004","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.mayocp.2017.02.011_bib15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/01.wnl.0000320506.79811.da","article-title":"The logopenic\/phonological variant of primary progressive aphasia","volume":"71","author":"Gorno-Tempini","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/1531-8257(199903)14:2<276::AID-MDS1013>3.0.CO;2-U","article-title":"A\u00a0kinematic study of progressive apraxia with and without dementia","volume":"14","author":"Caselli","year":"1999","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.53.4.795","article-title":"Pathologic heterogeneity in clinically diagnosed corticobasal degeneration","volume":"53","author":"Boeve","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.mayocp.2017.02.011_bib18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/archneur.56.10.1233","article-title":"Clinical and pathological evidence for a frontal variant of Alzheimer disease","volume":"56","author":"Johnson","year":"1999","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2017.02.011_bib19","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archneur.1985.04060100083029","article-title":"Diagnosis of Alzheimer's disease","volume":"42","author":"Khachaturian","year":"1985","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","article-title":"Staging of Alzheimer's disease-related neurofibrillary changes","volume":"16","author":"Braak","year":"1995","journal-title":"Neurobiol Aging"},{"issue":"4 suppl","key":"10.1016\/j.mayocp.2017.02.011_bib23","first-page":"S1","article-title":"Consensus Recommendations for the postmortem diagnosis of Alzheimer's disease","volume":"18","year":"1997","journal-title":"Neurobiol Aging"},{"issue":"12","key":"10.1016\/j.mayocp.2017.02.011_bib24","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of AB-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0197-4580(98)00090-6","article-title":"Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology","volume":"19","author":"Thal","year":"1998","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.mayocp.2017.02.011_bib26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12883-015-0403-4","article-title":"Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment","volume":"15","author":"Dugger","year":"2015","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/WNL.0000000000001831","article-title":"Multiple pathologies are common and related to dementia in the oldest-old: the 90+ study","volume":"85","author":"Kawas","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/jcbfm.2015.152","article-title":"Differential effects of ischemic vascular disease and Alzheimer's disease on brain atrophy and cognition","volume":"36","author":"Zheng","year":"2016","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"issue":"11","key":"10.1016\/j.mayocp.2017.02.011_bib29","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.0000000000002480","article-title":"Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies","volume":"86","author":"White","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnen\/nlv028","article-title":"Neuropathology of autosomal dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database","volume":"75","author":"Ringman","year":"2016","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.02.011_bib31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1474-4422(16)30029-1","article-title":"Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross sectional study","volume":"15","author":"Arvanitakis","year":"2016","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/neup.12189","article-title":"Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program","volume":"35","author":"Beach","year":"2015","journal-title":"Neuropathology"},{"issue":"19","key":"10.1016\/j.mayocp.2017.02.011_bib33","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer's disease in the United States (2010-2050) estimated using the 2010 Census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/(SICI)1099-1166(199906)14:6<481::AID-GPS959>3.0.CO;2-5","article-title":"Rates of dementia in three ethnoracial groups","volume":"14","author":"Gurland","year":"1999","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11065-008-9064-z","article-title":"Lifecourse social conditions and racial and ethnic patterns of cognitive aging","volume":"18","author":"Glymour","year":"2008","journal-title":"Neuropsychol Rev"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jalz.2016.03.004","article-title":"Neuropathologic differences by race from the National Alzheimer's Coordinating Center","volume":"12","author":"Graff-Radford","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"4791","key":"10.1016\/j.mayocp.2017.02.011_bib40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1126\/science.2880399","article-title":"The genetic defect causing familial Alzheimer's disease maps on chromosome 21","volume":"235","author":"St George-Hyslop","year":"1987","journal-title":"Science"},{"issue":"5082","key":"10.1016\/j.mayocp.2017.02.011_bib41","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1126\/science.1411576","article-title":"Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14","volume":"258","author":"Schellenberg","year":"1992","journal-title":"Science"},{"issue":"5226","key":"10.1016\/j.mayocp.2017.02.011_bib42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.7638622","article-title":"Candidate gene for the chromosome 1 familial Alzheimer's disease locus","volume":"269","author":"Levy-Lahad","year":"1995","journal-title":"Science"},{"issue":"6665","key":"10.1016\/j.mayocp.2017.02.011_bib43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/34910","article-title":"Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein","volume":"391","author":"De Strooper","year":"1998","journal-title":"Nature"},{"issue":"7409","key":"10.1016\/j.mayocp.2017.02.011_bib44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A\u00a0mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.mayocp.2017.02.011_bib45","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/1471-2164-14-290","article-title":"Origins of amyloid-\u03b2","volume":"14","author":"Tharp","year":"2013","journal-title":"BMC Genomics"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib46","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0197-4580(97)00151-6","article-title":"Generation of APLP2 KO mice and early postnatal lethality in APLP2\/APP double KO mice","volume":"18","author":"von Kock","year":"1997","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2009.07.041","article-title":"Amyloid precursor protein is required for convergent-extension movements during zebrafish development","volume":"335","author":"Joshi","year":"2009","journal-title":"Dev Biol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib48","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.cell.2013.05.002","article-title":"Dynamics of hippocampal neurogenesis in adult humans","volume":"153","author":"Spalding","year":"2013","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.mayocp.2017.02.011_bib49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/nan.12337","article-title":"Human adult neurogenesis across the ages: an immunohistochemical study","volume":"42","author":"Dennis","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/scrt77","article-title":"Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin","volume":"2","author":"Demars","year":"2011","journal-title":"Stem Cell Res Ther"},{"issue":"27","key":"10.1016\/j.mayocp.2017.02.011_bib51","doi-asserted-by":"crossref","first-page":"24264","DOI":"10.1074\/jbc.M111.227421","article-title":"Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells","volume":"286","author":"Freude","year":"2011","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/scrt80","article-title":"Amyloid precursor protein: more than just neurodegeneration","volume":"2","author":"Pimplikar","year":"2011","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib53","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","article-title":"Synaptic activity regulates interstitial fluid amyloid-\u03b2 levels in\u00a0vivo","volume":"48","author":"Cirrito","year":"2005","journal-title":"Neuron"},{"issue":"340","key":"10.1016\/j.mayocp.2017.02.011_bib54","doi-asserted-by":"crossref","first-page":"340ra72","DOI":"10.1126\/scitranslmed.aaf1059","article-title":"Amyloid-\u03b2 peptide protects against microbial infection in mouse and worm models of Alzheimer's disease","volume":"8","author":"Kumar","year":"2016","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib55","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","article-title":"TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model","volume":"160","author":"Wang","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.mayocp.2017.02.011_bib56","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nat Cell Biol"},{"issue":"23","key":"10.1016\/j.mayocp.2017.02.011_bib57","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1073\/pnas.1301175110","article-title":"Brain homogenates from human tauopathies induce tau inclusions in mouse brain","volume":"110","author":"Clavaguera","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7568","key":"10.1016\/j.mayocp.2017.02.011_bib58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature15369","article-title":"Evidence for human transmission of amyloid-\u03b2 pathology and cerebral amyloid angiopathy","volume":"525","author":"Jaunmuktane","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7326\/M15-2421","article-title":"Transmission of neurodegenerative disorders through blood transfusion: a cohort study","volume":"165","author":"Edgren","year":"2016","journal-title":"Ann Intern Med"},{"issue":"6740","key":"10.1016\/j.mayocp.2017.02.011_bib60","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after AB42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib62","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-\u03b2 peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"issue":"9634","key":"10.1016\/j.mayocp.2017.02.011_bib63","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase 1 trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib64","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2353\/ajpath.2006.060269","article-title":"Amyloid-\u03b2 peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis","volume":"169","author":"Patton","year":"2006","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","article-title":"A\u00a0critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease","volume":"76","author":"Karran","year":"2014","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib67","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/00005072-199311000-00006","article-title":"The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution","volume":"52","author":"Hyman","year":"1993","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.02.011_bib68","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/archneurol.2011.70","article-title":"Amyloid-dependent and amyloid-independent stages of Alzheimer disease","volume":"68","author":"Hyman","year":"2011","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib69","doi-asserted-by":"crossref","first-page":"e0125614","DOI":"10.1371\/journal.pone.0125614","article-title":"Passive immunization with phosphor-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models","volume":"10","author":"Sankaranarayanan","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00687663","article-title":"Quantitative histological studies on the aged human brain. I. Senile plaques and neurofibrillary tangles in \u201cnormal\u201d patients","volume":"16","author":"Dayan","year":"1970","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ana.410230206","article-title":"Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques","volume":"23","author":"Katzman","year":"1988","journal-title":"Ann Neurol"},{"issue":"5123","key":"10.1016\/j.mayocp.2017.02.011_bib72","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.mayocp.2017.02.011_bib73","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","article-title":"Association of apolipoprotein E allele \u03b54 with late-onset familial and sporadic Alzheimer's disease","volume":"43","author":"Saunders","year":"1993","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib74","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.21696","article-title":"Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age","volume":"65","author":"Kok","year":"2009","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neulet.2010.02.016","article-title":"Amyloid load in nondemented brains correlates with APOE e4","volume":"473","author":"Caselli","year":"2010","journal-title":"Neurosci Lett"},{"issue":"12","key":"10.1016\/j.mayocp.2017.02.011_bib76","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJM199603213341202","article-title":"Preclinical evidence of Alzheimer's disease in persons homozygous for the \u03b54 allele for apolipoprotein E","volume":"334","author":"Reiman","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib77","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1073\/pnas.061509598","article-title":"Declining brain activity in cognitively normal apolipoprotein E \u03b54 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease","volume":"98","author":"Reiman","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib78","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.410440226","article-title":"Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease","volume":"44","author":"Reiman","year":"1998","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib79","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1212\/WNL.59.5.746","article-title":"Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes","volume":"59","author":"den Heijer","year":"2002","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMoa0809437","article-title":"Longitudinal modeling of age-related memory decline and the APOE \u03b54 effect","volume":"361","author":"Caselli","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib81","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jalz.2013.01.004","article-title":"The neuropsychology of normal aging and preclinical Alzheimer's disease","volume":"10","author":"Caselli","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.mayocp.2017.02.011_bib82","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.1996.03530310034029","article-title":"Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: findings from the Nun Study","volume":"275","author":"Snowdon","year":"1996","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib83","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1073\/pnas.2635903100","article-title":"Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia","volume":"101","author":"Reiman","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib84","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JAD-2010-100129","article-title":"Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE \u03b54 allele, the major late-onset Alzheimer's susceptibility gene","volume":"22","author":"Valla","year":"2010","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1001\/jamaneurol.2013.4544","article-title":"Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross sectional imaging study","volume":"71","author":"Dean","year":"2014","journal-title":"JAMA Neurol"},{"issue":"16","key":"10.1016\/j.mayocp.2017.02.011_bib86","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-\u03b2 burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","article-title":"Apolipoprotein E \u03b54 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease","volume":"34","author":"Fleisher","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"10","key":"10.1016\/j.mayocp.2017.02.011_bib88","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaneurol.2015.1721","article-title":"Characterizing apolipoprotein E \u03b54 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal \u03b2-amyloid plaques","volume":"72","author":"Monsell","year":"2015","journal-title":"JAMA Neurol"},{"issue":"7618","key":"10.1016\/j.mayocp.2017.02.011_bib89","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib90","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib91","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","article-title":"An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease","volume":"71","author":"Jack","year":"2012","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib92","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00401-011-0826-y","article-title":"Alzheimer's disease is not \u201cbrain aging\u201d: neuropathological, genetic, and epidemiological human studies","volume":"12","author":"Nelson","year":"2011","journal-title":"Acta Neuropathol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.02.011_bib93","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2017.02.011_bib94","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study","volume":"11","author":"Reiman","year":"2012","journal-title":"Lancet Neurol"},{"issue":"4667","key":"10.1016\/j.mayocp.2017.02.011_bib95","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.6474172","article-title":"Alzheimer's disease: cell-specific pathology isolates the hippocampal formation","volume":"225","author":"Hyman","year":"1984","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib96","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.42.1.183","article-title":"MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease","volume":"42","author":"Jack","year":"1992","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib97","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jmri.21049","article-title":"The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods","volume":"27","author":"Jack","year":"2008","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib98","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.neurobiolaging.2013.09.039","article-title":"Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size","volume":"35","author":"Yu","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"7","key":"10.1016\/j.mayocp.2017.02.011_bib99","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1212\/WNL.0000000000002979","article-title":"Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia","volume":"87","author":"Knopman","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib100","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib101","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In\u00a0vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F18)","volume":"51","author":"Wong","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib102","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.02.011_bib103","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib104","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.mayocp.2017.02.011_bib105","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid \u03b2 plaques in Alzheimer's disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.mayocp.2017.02.011_bib106","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/NEN.0000000000000114","article-title":"Theoretical impact of florbetapir (18F) amyloid imaging on diagnosis of Alzheimer dementia and detection of preclinical cortical amyloid","volume":"73","author":"Beach","year":"2014","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib107","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib108","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"issue":"pt 5","key":"10.1016\/j.mayocp.2017.02.011_bib109","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.mayocp.2017.02.011_bib110","first-page":"1920","article-title":"FDG-PET imaging in patients with pathologically verified dementia","volume":"41","author":"Hoffman","year":"2000","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.mayocp.2017.02.011_bib111","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.02.011_bib112","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.wnl.0000256043.50901.e3","article-title":"Fluctuations of CSF amyloid-\u03b2 levels: implications for a diagnostic and therapeutic biomarker","volume":"68","author":"Bateman","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mayocp.2017.02.011_bib113","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","article-title":"The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers","volume":"7","author":"Mattsson","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.mayocp.2017.02.011_bib114","doi-asserted-by":"crossref","first-page":"e1600947","DOI":"10.1126\/sciadv.1600947","article-title":"A\u00a0protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer's disease","volume":"2","author":"Freer","year":"2016","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib115","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","article-title":"Role of genes and environments for explaining Alzheimer disease","volume":"63","author":"Gatz","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib116","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/gim.2015.117","article-title":"The genetic landscape of Alzheimer disease: clinical implications and perspectives","volume":"18","author":"Van Cauwenberghe","year":"2016","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib117","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00019052-200404000-00003","article-title":"Down syndrome and \u03b2-amyloid deposition","volume":"17","author":"Head","year":"2004","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"10.1016\/j.mayocp.2017.02.011_bib118","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1084\/jem.20150892","article-title":"Qualitative changes in human \u03b3-secretase underlie familial Alzheimer's disease","volume":"212","author":"Szaruga","year":"2015","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib119","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/gepi.1370090302","article-title":"Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world","volume":"9","author":"Gerdes","year":"1992","journal-title":"Genet Epidemiol"},{"issue":"pt 4","key":"10.1016\/j.mayocp.2017.02.011_bib120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1469-1809.1999.6340301.x","article-title":"Apolipoprotein E (APOE) allele distribution in the world: is APOE*4 a \u2018thrifty\u2019 allele?","volume":"63","author":"Corbo","year":"1999","journal-title":"Ann Hum Genet"},{"issue":"16","key":"10.1016\/j.mayocp.2017.02.011_bib121","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"issue":"pt A","key":"10.1016\/j.mayocp.2017.02.011_bib122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases","volume":"72","author":"Huang","year":"2014","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.mayocp.2017.02.011_bib123","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/mp.2011.52","article-title":"APOE and Alzheimer disease: a major gene with semi-dominant inheritance","volume":"16","author":"Genin","year":"2011","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib124","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/tpj.2009.69","article-title":"A\u00a0TOMM40 variable length polymorphism predicts the age of late-onset Alzheimer's disease","volume":"10","author":"Roses","year":"2009","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ana.410360614","article-title":"Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies","volume":"36","author":"Nalbantoglu","year":"1994","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.mayocp.2017.02.011_bib126","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","article-title":"Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Knopman","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib127","first-page":"382","article-title":"Concurrent Alzheimer's pathology in patients with clinical normal pressure hydrocephalus: correlation with high-volume lumbar puncture results, cortical brain biopsies, and outcomes","volume":"124","author":"Pomeraniec","year":"2016","journal-title":"J\u00a0Neurosurg"},{"issue":"12","key":"10.1016\/j.mayocp.2017.02.011_bib128","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1001\/jamaneurol.2016.3792","article-title":"The clinical impact of amyloid PET: is it worth the cost?","volume":"73","author":"Caselli","year":"2016","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0809578","article-title":"Disclosure of APOE genotype for risk of Alzheimer's disease","volume":"361","author":"Green","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2017.02.011_bib130","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.mayocp.2014.05.016","article-title":"Public perceptions of presymptomatic testing for Alzheimer disease","volume":"89","author":"Caselli","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib131","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A\u00a024-week, double-blind, placebo controlled trial of donepezil in patients with Alzheimer's disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"issue":"7184","key":"10.1016\/j.mayocp.2017.02.011_bib132","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"R\u00f6sler","year":"1999","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.mayocp.2017.02.011_bib133","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.mayocp.2017.02.011_bib134","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2017.02.011_bib135","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.mayocp.2017.02.011_bib136","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","article-title":"Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial","volume":"289","author":"Shumaker","year":"2003","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.mayocp.2017.02.011_bib137","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocp.2017.02.011_bib138","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial","volume":"300","author":"Aisen","year":"2008","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.mayocp.2017.02.011_bib139","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2008.683","article-title":"Ginkgo biloba for prevention of dementia: a randomized controlled trial","volume":"300","author":"DeKosky","year":"2008","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.mayocp.2017.02.011_bib140","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2017.02.011_bib141","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ana.20854","article-title":"Mediterranean diet and risk for Alzheimer's disease","volume":"59","author":"Scarmeas","year":"2006","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib142","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archneurol.2009.297","article-title":"Physical exercise, aging, and mild cognitive impairment: a population-based study","volume":"67","author":"Geda","year":"2010","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2017.02.011_bib143","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/EDE.0000000000000513","article-title":"Late-life cognitive activity and dementia: a systematic review and bias analysis","volume":"27","author":"Sajeev","year":"2016","journal-title":"Epidemiology"},{"issue":"9984","key":"10.1016\/j.mayocp.2017.02.011_bib144","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A\u00a02 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocp.2017.02.011_bib145","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1212\/WNL.53.9.1942","article-title":"Rate of memory decline in AD is related to education and occupation: cognitive reserve?","volume":"53","author":"Stern","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2017.02.011_bib146","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00401-013-1226-2","article-title":"Cognitive and social lifestyle: links to neuropathology and cognition in later life","volume":"127","author":"Bennett","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.mayocp.2017.02.011_bib147","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S1355617715000016","article-title":"Sex-based memory advantages and cognitive aging: a challenge to the cognitive reserve construct?","volume":"21","author":"Caselli","year":"2015","journal-title":"J\u00a0Int Neuropsychol Soc"},{"issue":"9916","key":"10.1016\/j.mayocp.2017.02.011_bib148","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2017.02.011_bib149","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"15","key":"10.1016\/j.mayocp.2017.02.011_bib150","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2017.02.011_bib151","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Quetiapine for agitation or psychosis in patients with dementia and parkinsonism","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.mayocp.2017.02.011_bib152","unstructured":"US Food and Drug Administration. Safety alerts for human medical products. https:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm150688.htm. Accessed March 16, 2017."},{"issue":"22","key":"10.1016\/j.mayocp.2017.02.011_bib153","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications","volume":"353","author":"Wang","year":"2005","journal-title":"N\u00a0Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617301581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617301581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T09:50:54Z","timestamp":1617616254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619617301581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":153,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0025619617301581"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.02.011","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer Disease","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}